Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Consensus PT from Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have earned an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $22.50.

DCTH has been the topic of several analyst reports. Wall Street Zen cut shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Zacks Research downgraded Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. BTIG Research lowered their price objective on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Evercore set a $27.00 price objective on Delcath Systems in a research note on Thursday, February 26th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DCTH. California State Teachers Retirement System bought a new stake in shares of Delcath Systems in the 2nd quarter valued at $26,000. Russell Investments Group Ltd. bought a new position in Delcath Systems during the third quarter worth $29,000. Tower Research Capital LLC TRC acquired a new position in Delcath Systems in the second quarter valued at $40,000. Legal & General Group Plc acquired a new position in Delcath Systems in the second quarter valued at $46,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Delcath Systems during the second quarter valued at $151,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Price Performance

NASDAQ:DCTH opened at $11.72 on Wednesday. The firm’s 50 day simple moving average is $10.82 and its 200 day simple moving average is $10.14. Delcath Systems has a one year low of $8.12 and a one year high of $15.57. The company has a market cap of $404.57 million, a PE ratio of 1,172.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. Equities research analysts expect that Delcath Systems will post -0.88 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.